SCNI Scinai Immunotherapeutics Ltd.
Data as of close
Healthcare · Biological Products, (No Diagnostic Substances)
Scinai Immunotherapeutics Ltd. (SCNI) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry. Shares last traded at $0.45, 96.8% below their 52-week high. Over the past year the stock is down 97.1%. Net profit margin is -633.6%, below the peer median of -1.6%. Revenue grew 99.2% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. SCNI split history →
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2025-12-31. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2023 | -$0.30 | 2023-05-15 |
| FY 2022 | -$1.00 | 2023-04-17 |
| Q1 2022 | -$0.30 | — |
| FY 2021 | -$2.00 | — |
Biological Products, (No Diagnostic Substances) peers
SCNI vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Data as of close
| AMGN | Amgen | $249.1B | 28.49 | 6.54 | 23.0% | -1.01% |
| GILD | Gilead Sciences | $207.8B | — | 6.70 | -12.5% | -1.70% |
| MRNA | Moderna | $91.2B | — | — | — | +3.39% |
| RVMD | Revolution Medicines, Inc. | $41.6B | — | — | — | +3.15% |
| BIIB | Biogen | $36.8B | 105.92 | 3.57 | 3.4% | +0.00% |
| EXEL | Exelixis, Inc. | $17.7B | 19.94 | 7.07 | 35.5% | +3.24% |
| NBIX | Neurocrine Biosciences Inc | $16.7B | 23.76 | 4.51 | 19.0% | +13.37% |
| HALO | Halozyme Therapeutics, Inc. | $14.6B | 35.29 | 8.77 | 24.9% | -0.26% |
| TECH | Bio-Techne | $11.4B | 62.76 | 9.39 | 15.0% | +0.00% |
| RGEN | Repligen Corp | $11.4B | — | 14.15 | -1.5% | +3.07% |
| QGEN | Qiagen N.V. | $10.9B | 25.72 | 5.23 | 20.3% | +0.10% |
| KYMR | Kymera Therapeutics, Inc. | $10.9B | — | — | — | -0.36% |
| PCVX | Vaxcyte, Inc. | $9.1B | — | — | — | +0.40% |
| KRYS | Krystal Biotech, Inc. | $9.0B | 40.14 | 19.23 | 47.9% | +3.04% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.